Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy

Reslizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces exacerbation frequency and improves lung function, asthma control and quality of life in adults with severe eosinophilic asthma, as demonstrated in Phase III studies. This secondary analysis assessed reslizumab's effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Brusselle, Guy, Canvin, Janice, Weiss, Sivan, Sun, Shawn X., Buhl, Roland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570512/
https://www.ncbi.nlm.nih.gov/pubmed/28845430
http://dx.doi.org/10.1183/23120541.00004-2017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570512/
https://www.ncbi.nlm.nih.gov/pubmed/28845430
http://dx.doi.org/10.1183/23120541.00004-2017

Ejemplares similares